Leadership Overview
Catalent has 7 executives leading key functions including revenue generation, financial oversight, human capital management, and global pharmaceutical operations.
Focused on advancing health through innovative softgel technology, Catalent delivers essential pharmaceutical solutions to global markets while maintaining a premier manufacturing network across Latin America.
Focused on advancing health through innovative softgel technology, Catalent delivers essential pharmaceutical solutions to global markets while maintaining a premier manufacturing network across Latin America.
Leadership Roles at Catalent
Matti Masanovich - Senior Vice President & Chief Financial Officer
Matti Masanovich, the Senior Vice President & Chief Financial Officer at Catalent, manages the entire fiscal health and capital allocation strategy for the organization. Overseeing global financial reporting, the Senior Vice President & Chief Financial Officer ensures compliance with international standards while supporting the development of plant-based softgel technologies. This leadership role involves balancing investment in manufacturing infrastructure with the need for sustained profitability across diverse product sectors. By monitoring operational costs and supply chain efficiency, Matti Masanovich directly impacts the company's ability to scale production. Masanovich maintains rigorous oversight of budgetary controls, ensuring that resources align with the long-term mission of delivering high-quality pharmaceutical solutions. The Senior Vice President & Chief Financial Officer also collaborates with the board to communicate financial performance and strategic growth initiatives to stakeholders, reinforcing the market position of the firm within the pharmaceutical manufacturing landscape.
Chris Hajjar - Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer
Chris Hajjar, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer at Catalent, executes complex financial modeling and planning for the biologics division. Overseeing the financial health of specialized pharmaceutical projects, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer ensures that capital investments support the development of advanced drug delivery systems. This leadership role involves analyzing market trends to forecast revenue growth within the biologics sector. By providing actionable financial insights, Chris Hajjar directly impacts the strategic decision-making process regarding new product launches. Hajjar coordinates with operational leaders to optimize resource allocation, ensuring that the biologics segment maintains its competitive edge. The Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer also monitors the financial performance of regional manufacturing networks, ensuring that fiscal targets align with the overarching goals of the organization.
Aris Gennadios - Group President, Pharma & Consumer Health
Aris Gennadios, the Group President, Pharma & Consumer Health at Catalent, directs the operational strategy for the pharmaceutical and consumer health divisions. Overseeing the production of softgel formulations, the Group President, Pharma & Consumer Health ensures that manufacturing processes meet the highest quality standards for global markets. This leadership role involves managing the lifecycle of OTC and RX products, from initial development to final supply. By optimizing the manufacturing network across Latin America, Aris Gennadios directly impacts the availability and innovation of essential health products. Gennadios coordinates with cross-functional teams to streamline production workflows and enhance operational efficiency. The Group President, Pharma & Consumer Health also leads the expansion of the product portfolio, ensuring that the company remains responsive to the needs of the global health and beauty sectors. Through strategic oversight, Gennadios maintains the company's position as a premier provider of pharmaceutical solutions.
David McErlane - Group President, Biologics
David McErlane, the Group President, Biologics at Catalent, leads the strategic direction and operational execution of the biologics business unit. Overseeing the development of advanced pharmaceutical forms, the Group President, Biologics ensures that the company delivers cutting-edge solutions to the global health market. This leadership role involves managing complex manufacturing processes and ensuring that the biologics division remains at the forefront of scientific innovation. By driving operational excellence, David McErlane directly impacts the company's ability to meet the rigorous demands of the pharmaceutical industry. McErlane coordinates with research and development teams to accelerate the delivery of new therapies to market. The Group President, Biologics also oversees the expansion of global manufacturing capabilities, ensuring that the organization can scale production to meet international demand. Through focused leadership, McErlane ensures that the biologics division contributes significantly to the overall growth and success of the company.
Sarah Hauer - Chief Revenue Officer
Sarah Hauer, the Chief Revenue Officer at Catalent, directs all commercial growth strategies across the global health and beauty sectors. Overseeing the expansion of softgel formulations, the Chief Revenue Officer ensures alignment between market demand and manufacturing output. This leadership role involves identifying new opportunities within the OTC and nutritional supplement industries to maximize market share. By optimizing sales pipelines and client engagement, Sarah Hauer directly impacts the company's revenue trajectory. Hauer secures long-term financial stability through the cultivation of strategic partnerships and the implementation of data-driven pricing models. The Chief Revenue Officer also coordinates with regional teams to ensure consistent service delivery across Latin American operations. Through rigorous analysis of consumer trends, Hauer drives the adoption of advanced pharmaceutical forms, ensuring that the organization remains at the forefront of the competitive global health market.
Lisa Evoli - Chief Human Resources Officer
Lisa Evoli, the Chief Human Resources Officer at Catalent, architects the global talent strategy and organizational culture necessary to support complex pharmaceutical manufacturing. Overseeing workforce development, the Chief Human Resources Officer ensures that the company attracts and retains top-tier expertise in softgel technology and advanced pharmaceutical sciences. This leadership role involves designing comprehensive training programs that align with the company's 85-year history of innovation. By fostering an inclusive environment, Lisa Evoli directly impacts employee engagement and operational productivity across Latin American and global facilities. Evoli manages the integration of human capital initiatives with broader business objectives, ensuring that the workforce remains agile in the face of evolving market demands. The Chief Human Resources Officer also leads efforts to standardize performance management systems, ensuring that every team member contributes effectively to the delivery of high-quality OTC and RX products for global health clients.

Kassandra Walsh - Senior Account Director & Chief Revenue Officer
Kassandra Walsh, the Senior Account Director & Chief Revenue Officer at Catalent, drives client acquisition and retention strategies specifically for the beauty and nutritional supplement sectors. Overseeing key account relationships, the Senior Account Director & Chief Revenue Officer ensures that client needs for chewable softgels and other advanced forms are met with precision. This leadership role involves managing high-value contracts and negotiating terms that support long-term business growth. By identifying emerging market opportunities, Kassandra Walsh directly impacts the company's footprint in the consumer health space. Walsh collaborates with product development teams to ensure that client feedback informs future innovation. The Senior Account Director & Chief Revenue Officer also oversees the implementation of regional sales strategies, ensuring that the company's manufacturing capabilities are effectively communicated to potential partners. Through consistent engagement, Walsh secures the loyalty of major clients, reinforcing the company's reputation as a leader in pharmaceutical manufacturing.
Explore Leadership Teams in Manufacturing
Founded in 1974, Apotex is a proud Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
Company Leadership DA

JB
AA
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is heaquartered in Mumbia, India. Sun Pharma is a global pharmaceutical company that develops, manufactures, and markets specialty medicines, generic drugs, complex generics, and active pharmaceutical ingredients. Its primary industry is pharmaceutical manufacturing, with pharmaceutical research and development as a secondary activity.
Company Leadership JG
GS
MP
Tabuk Pharmaceuticals, established in 1994 and headquartered in Riyadh, is the largest privately-owned pharmaceutical company in Saudi Arabia, with a significant presence in the Middle East and North Africa (MENA) region. The company focuses on delivering high-quality and affordable generic medicines across various therapeutic areas, including anti-infectives, cardiovascular, and diabetes care. Committed to sustainability and innovation, Tabuk Pharma invests in differentiated technologies to enhance global healthcare. Their mission emphasizes integrity, respect for people, and stakeholder-centric values.
Company Leadership IS
DB
HR

IOLCP is a leading manufacturer and supplier of Active Pharmaceutical Ingredients (API) and specialty chemicals, including Ethyl Acetate, which is recognized for its environmentally friendly properties. The company serves pharmaceutical companies globally by providing essential products for key medicines and is committed to sustainable practices and corporate social responsibility. With a strong focus on research and development, IOLCP aims to expand its value-added services in the API market while fostering green chemistry. The organization prides itself on its dedicated workforce and aims to create lasting value for both the planet and communities.
Company Leadership GP
PK
DS